Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

Jefferies analyst Brent Thill maintained a Buy rating on Microsoft Corporation (NASDAQ:MSFT) with a steady price target of ...

In a report released on January 20, Matthew Hedberg from RBC Capital maintained a Buy rating on ServiceNow (NOW – Research Report), with a ...

TD Cowen analyst Shaul Eyal reiterated a Buy rating on Check Point (CHKP – Research Report) today and set a price target of $215.00.Invest with ...

Confluent stock is currently down 71% from its all-time high, which was set during the tech frenzy in 2021. It was unquestionably overvalued back then, but the majority of analysts tracked by The Wall ...

Stocks trading under $10 can be attractive for investors looking to scoop up some cheap shares. Unfortunately, quality stocks ...

The latest Apple stock downgrade centers around iPhone sales and the weakening consumer electronics market. Here's what ...

Bank of America analyst Lorraine Hutchinson reiterated a Buy rating on Bath & Body Works and maintained its $45 price target.

FinVolution's international expansion and low delinquency rates drive growth. See why FINV stock is a Strong Buy with a strong balance sheet and dividends.

UBS Maintains Buy on Netflix, Raises Price Target to $1150 Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings ...